Icosavax ( ) - 株価, ニュースと分析Nasdaq:ICVX

ICVX 株式概要

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. 詳細

ICVX ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

リスク分析

収益が 100 万ドル未満 ( $0 )

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

過去3か月間の株価の変動

Icosavax, Inc. 競合他社

Vir Biotechnology

NasdaqGS:VIR

US$980.6m

AnaptysBio

NasdaqGS:ANAB

US$677.6m

REGENXBIO

NasdaqGS:RGNX

US$475.1m

MeiraGTx Holdings

NasdaqGS:MGTX

US$463.4m

価格と性能

の歴代最高値、変動、値下がりまとめIcosavax
過去の株価
現在の株価	US$15.31
52週高値	US$16.11
52週安値	US$4.75
ベータ	1.28
11ヶ月の変化	-0.78%
3ヶ月変化	50.84%
1年変化	68.80%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	-56.22%

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

株主還元

	ICVX	US Biotechs	US 市場
7D	-0.6%	2.5%	2.2%
1Y	68.8%	16.1%	31.6%

業界別リターン: ICVX過去 1 年間で16.1 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: ICVX過去 1 年間で31.6 % の収益を上げたUS市場を上回りました。

価格変動

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement	15.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

安定した株価: ICVXの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ICVXの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2017	60	Adam Simpson	icosavax.com

Icosavax, Inc. 基礎のまとめ

Icosavax の収益と売上を時価総額と比較するとどうか。
ICVX 基礎統計学
時価総額	US$777.79m
収益（TTM）	-US$96.71m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-8.0x

PER（株価収益率

ICVX は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ICVX 損益計算書（TTM）
収益	US$0
売上原価	US$70.04m
売上総利益	-US$70.04m
その他の費用	US$26.67m
収益	-US$96.71m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.90
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

ICVX の長期的なパフォーマンスは？

過去の実績と比較を見る

ICVX 株式概要

リスク分析

Icosavax, Inc. 競合他社

NasdaqGS:VIR

US$980.6m

NasdaqGS:ANAB

US$677.6m

NasdaqGS:RGNX

US$475.1m

NasdaqGS:MGTX

US$463.4m

価格と性能

最新ニュース

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

株主還元

価格変動

会社概要

Icosavax, Inc. 基礎のまとめ

0.0x

-8.0x